지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2014.1
- 수록면
- 399 - 401 (3page)
이용수
초록· 키워드
오류제보하기
CML is a myeloproliferative disease characterized by the Phila- delphia (Ph) chromosome, in which the oncogenic BCR-ABL1 fusion gene encodes a constitutively active tyrosine kinase. First- line treatment using the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib has significantly changed the disease course of CML [1].
However, some patients develop resistance to this agent, largely due to point mutations within the ABL1 kinase domain (KD) [2, 3]. Resistance to imatinib may be overcome by treatment with second-line TKIs, including dasatinib, nilotinib, and bosutinib, which are active against most mutations; however, some muta- tions bring about resistance to these second-line drugs as well [4-6]. Therefore, a mutation analysis is recommended when choosing a second-line TKI [7]. We describe a CML patient who rapidly progressed to blast crisis following the sequential acquisi- tion of ABL1 KD mutations with a complex karyotype.
목차
등록된 정보가 없습니다.
참고문헌 (14)
참고문헌 신청
Baccarani M / 2009 / Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet / J Clin Oncol 27 : 6041 ~ 6051
Ernst T / 2009 / A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatin
Gorre ME / 2001 / Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification / Science 293 : 876 ~ 880
Hehlmann R / 1997 / Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal’s index and a new score. German chronic myeloid leu
Hochhaus A / 2002 / Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy / Leukemia 16 : 2190 ~ 2196
Ernst T / 2009 / A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatin
Gorre ME / 2001 / Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification / Science 293 : 876 ~ 880
Hehlmann R / 1997 / Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal’s index and a new score. German chronic myeloid leu
Hochhaus A / 2002 / Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy / Leukemia 16 : 2190 ~ 2196
이 논문의 저자 정보
최근 본 자료
댓글(0)
0